Difficulty: Medium
Average Score: 86%
Practice
You are evaluating a 6-mo-old girl with a firm right suprarenal mass. Histologically, there is no bony involvement, 10% bone marrow involvement, subcutaneous nodules involvement, and massive abdominal mass. The N-myc oncogene is not amplified. According to the international neuroblastoma staging system, the infant is stratified as
Correct answer
D
Rationale
In this case, the correct answer is D) stage IV S. This infant's presentation with a firm right suprarenal mass, 10% bone marrow involvement, subcutaneous nodules involvement, and a massive abdominal mass corresponds to stage IV S in the international neuroblastoma staging system. Stage IV S indicates a special category where the tumor has spread to distant sites, such as the liver, skin, or bone marrow, but the child is younger than 18 months and the tumor has specific genetic features like absence of N-myc amplification.
Option A) stage I is incorrect because this stage is characterized by a localized tumor without regional lymph node involvement. Option B) stage II A is incorrect as it involves unilateral tumor with incomplete resection. Option C) stage III is not applicable as it involves tumor unresectable due to involvement of major blood vessels.
Understanding neuroblastoma staging is crucial for healthcare providers working in pediatric oncology. It helps in determining prognosis, guiding treatment decisions, and communicating effectively with patients' families. This question highlights the importance of considering both clinical and genetic features in stratifying neuroblastoma cases, emphasizing the need for a comprehensive approach in managing pediatric oncology cases.
Option A) stage I is incorrect because this stage is characterized by a localized tumor without regional lymph node involvement. Option B) stage II A is incorrect as it involves unilateral tumor with incomplete resection. Option C) stage III is not applicable as it involves tumor unresectable due to involvement of major blood vessels.
Understanding neuroblastoma staging is crucial for healthcare providers working in pediatric oncology. It helps in determining prognosis, guiding treatment decisions, and communicating effectively with patients' families. This question highlights the importance of considering both clinical and genetic features in stratifying neuroblastoma cases, emphasizing the need for a comprehensive approach in managing pediatric oncology cases.